Bioventus (BVS) Cash & Current Investments (2020 - 2026)

Bioventus' Cash & Current Investments history runs 7 years deep, the most recent figure standing at $35.8 million for Q1 2026.

• Quarterly Cash & Current Investments rose 57.21% year-over-year to $35.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.8 million (up 57.21% YoY) and the FY2025 annual result came in at $51.2 million, up 23.22% from the prior year.
• Cash & Current Investments was $35.8 million for Q1 2026 at Bioventus, down from $51.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $51.2 million in Q4 2025 and bottomed at $22.8 million in Q1 2025.
• A 5-year average of $35.6 million and a median of $34.4 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments slumped 75.75% — and 2024, when it surged 60.56%.
• Bioventus' Cash & Current Investments stood at $30.2 million in 2022, then climbed by 22.36% to $37.0 million in 2023, then grew by 12.49% to $41.6 million in 2024, then increased by 23.22% to $51.2 million in 2025, then sank by 30.04% to $35.8 million in 2026.
• Business Quant data shows BVS's Cash & Current Investments at $35.8 million in Q1 2026, $51.2 million in Q4 2025, and $42.2 million in Q3 2025.